The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Alison M. Paterson(Brigham and Women's Hospital), Arlene H. Sharpe(Broad Institute), Anil Chandraker(Brigham and Women's Hospital), Keturah Brown(Harvard University), Bruce R. Blazar(University of Minnesota Medical Center), Mary Keir(Brigham and Women's Hospital), Vijay K. Vanguri(University of Massachusetts Chan Medical School), Gordon J. Freeman(Dana-Farber Cancer Institute), Leonardo V. Riella(Brigham and Women's Hospital), Mohamed H. Sayegh(Brigham and Women's Hospital)
Cited by 205
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
|Nature Medicine|2007|2.2k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k